Compare ADMA Biologics Inc (ADMA) vs iShares Core S&P 500 ETF (IVV) Price & Performance

ADMA Biologics IncTrade

iShares Core S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs iShares Core S&P 500 ETF — how do they compare? ADMA Biologics Inc trades at $9.52 (market cap $2.19B), while iShares Core S&P 500 ETF trades at $781.85. The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

	ADMA	IVV
Market Cap	$2.19B	—
Sector	Health	Broad Market / Factor
52-Week High	$20.38	$776.81
52-Week Low	$7.60	$634.93
Enterprise Value	$2.26B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.

Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $776.18, down 0.07% with a bullish technical outlook from moving averages but overbought RSI signals. Recent news highlights record highs and institutional activity, with JPMorgan raising its S&P 500 target to 8,000 amid strong earnings growth. The ETF shows resilience despite valuation concerns.

Outlook remains positive due to AI-driven earnings growth, but risks include high valuations and market volatility. Investors benefit from broad market exposure, yet should monitor inflation reports and geopolitical events that could trigger pullbacks.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ADMA

ADMA Biologics sees 24% ASCENIV revenue growth in Q2 despite lowered long-term targetsSeeking Alpha · 21 hours agoBullish Investigation launched into ADMA Biologics for alleged channel-stuffing to boost ASCENIV sales.Newsfile Corp · 1 day agoBearish View details →

IVV

S&P 500 ETFs forecast strong dividend growth, with IVV leading in 2026 distributions.Seeking Alpha · 7 hours agoBullish WisdomTree U.S. Total Dividend ETF (DTD) rated 'hold' for balanced factors but overlaps 57% with S&P 500 ETFs.Seeking Alpha · 2 days agoNeutral View details →

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.